The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Biomarker-driven prospective clinical trial in renal cell carcinoma: Developing machine learning models to allocate patients to treatment arms using RNA sequencing.
 
Anupama Reddy
No Relationships to Disclose
 
Scott Mattox Haake
Consulting or Advisory Role - Pionyr
 
Katy Beckermann
Consulting or Advisory Role - Alpine Immune Sciences; Aravive; AstraZeneca; AVEO; Bristol-Myers Squibb; Exelixis; Merck; Sanofi; Seagen
Research Funding - Aravive (Inst); ArsenalBio (Inst); Bristol-Myers Squibb; Merck Sharp & Dohme; Pionyr (Inst)
 
Alex Nesta
No Relationships to Disclose
 
Adnan Derti
No Relationships to Disclose
 
Wendy Kimryn Rathmell
Stock and Other Ownership Interests - Caribou Biosciences (I); Nirogy Therapeutics (I); Sitryx (I)
Consulting or Advisory Role - Caribou Biosciences (I); Nirojy (I); Sitryx (I)
Research Funding - Incyte (I); Peloton Therapeutics (Inst)
Patents, Royalties, Other Intellectual Property - ClearCode34 Risk prediction biomarker for kidney cancer; hERV 3-2 expression as a biomarker of response to immunotherapy
 
Nanguneri Nirmala
No Relationships to Disclose
 
Brian I. Rini
Leadership - MashupMD; MJH Life Sciences
Stock and Other Ownership Interests - PTC Therapeutics
Consulting or Advisory Role - Alkermes; Aravive; Arrowhead Pharmaceuticals; Athenex; AVEO; Bristol-Myers Squibb; Corvus Pharmaceuticals; Debiopharm Group; Eisai; EUSA Pharma; Genentech; HiberCell; Merck; NiKang Therapeutics; Pfizer; Surface Oncology
Research Funding - ADC Therapeutics (Inst); Adela (Inst); Aravive (Inst); Arcus Biosciences (Inst); Arrowhead Pharmaceuticals (Inst); AstraZeneca/MedImmune (Inst); AVEO (Inst); Bristol-Myers Squibb (Inst); Daiichi Sankyo/UCB Japan (Inst); Dracen (Inst); Dragonfly Therapeutics (Inst); Exelixis (Inst); Gilead Sciences (Inst); HiberCell (Inst); Incyte (Inst); Janssen (Inst); Merck (Inst); Pfizer (Inst); Pionyr (Inst); Point Therapeutics (Inst); Roche/Genentech (Inst); Seagen (Inst); Stata (Inst); Surface Oncology (Inst); Vasgene Therapeutics (Inst)
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Merck; Pfizer